Home

The firm

Team

Portfolio

Investors

Connect

  • Loading stock data...

The Nordicus Portfolio

We are committed to investing in transformative ideas and businesses that have the potential to drive positive change and deliver meaningful impact

We are meticulously building our portfolio, selecting companies that align with our strategic vision and inclusion criteria. This deliberate approach ensures that each addition not only complements our mission of delivering value for our shareholders but also drives meaningful growth and impact for our portfolio companies.

By thoughtfully curating our portfolio, we are creating a foundation for sustained growth at Nordicus by empowering companies to reach their full potential, and delivering long-term value to our shareholders.

Transactions

200,000

Common Stock Purchase

Acquired By

November, 2024

12,000,000

Common Stock Purchase

Acquired By

November, 2024

3,800,000

Common Stock Purchase

Acquired By

May, 2024

Kim Mücke

Member, Board of Directors

Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.

Andrew Ritter

Member, Board of Directors

Mr. Ritter is a seasoned healthcare executive with over two decades of leadership experience across biotechnology, digital health, and other healthcare technologies. He has successfully led multiple company exits, taken a company public on NASDAQ, and advised leading private equity and venture capital firms throughout the investment lifecycle.

He began his career as the founder and CEO of Ritter Pharmaceuticals, a microbiome-based biotech company. Over 17 years, he advanced the company from early-stage development through Phase III clinical trials, led its IPO onto the NASDAQ, and later merged the company with QualigenTherapeutics. Following that success, Mr. Ritter led a turnaround and successful exit of Docbot, an AI-driven MedTech company. He is currently an Entrepreneur in Residence at Khosla Ventures, and serves as CEO of portfolio company Cairns Health, an AI-powered remote care solutions to support Home and Senior Care.

He has also served as a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth. Mr. Ritter holds a B.A. in Political Science from the University of Southern California and an M.B.A. from the Wharton School of the University of Pennsylvania.